You are here: Industry Insights > Drug development

News List

EU rules may be stifling Britain's biotech industry pharmafile
November 20, 2018
EU rules are stifling Britain’s biotech industry, according to companies who talked to British newspaper The Daily Telegraph.
FDA announces steps to modernise drug development and improve efficiency europeanpharmaceuticalreview
October 19, 2018
US FDA commissioner has announced steps to modernise the drug development process to improve efficiency and promote innovation…
GSK grabs new drug development head from Boehringer expressbpd
September 21, 2018
GlaxoSmithKline has hired Chris Corsico from German drugmaker Boehringer Ingelheim to fill the new role of senior vice-president development as the company reshapes its research strategy, a spokesman for the British group said recently.
GSK invests $300m in 23andMe under drug development deal pharmaceutical-technology
July 27, 2018
GlaxoSmithKline (GSK) has formed a multi-year alliance with genetics firm 23andMe to carry out research and development for new medicines and potential cures.
BMS collaborates with Tsinghua University for drug development biospectrumasia
July 25, 2018
The collaboration is an expansion of an existing relationship between Bristol-Myers Squibb and Tsinghua University that began in 2012.
Analysis of New Drug R&D Strategies: Advantages of First-to-Market Drugs Shrinking while Latecomer me-better Drugs Surpassing Mr. Nanguo
June 15, 2018
In the new drug development, pursuing the marketing of the first product of its variety is always the highest goal of pharmaceutical enterprises
WuXi AppTec to expand drug development testing services biospectrumasia
April 23, 2018
The grand opening event was honored by the presence of state and local officials including State Senator Linda Greenstein
Doctor Calls for Alzheimer’s Boot Camps to Spur Drug Development biospace
April 10, 2018
It’s no secret that drugmakers have struggled to develop a therapeutic to treat or halt the onset of Alzheimer’s disease.
STA Pharmaceutical sees rapid growth in MAH Programs in China pharmaasia
December 27, 2017
Since the launch of the MAH pilot, STA has undertaken eight development programmes, and anticipates carrying on 10+ MAH projects in 2018.
Schizophrenia drugs market will be worth US$7.9 billion by 2022 pharmaasia
November 20, 2017
The report expects the schizophrenia market to be driven by improved drug delivery technologies, LAI availability and more patients seeking treatment.

Previous page 1 2 3 4 5 6 Next page